coins payment, Overview

Xinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.Contemporary Amperex Technology Co., Limited announced that the company plans to pay dividends with 15% of the net profit in the first three quarters of 2024, that is, 5.4 billion yuan as the total distribution, and distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares. In addition, Contemporary Amperex Technology Co., Limited and Stellantis plan to jointly set up a joint venture company in Spain, with each party holding 50% of the shares. The estimated total investment of the battery factory is 4.038 billion euros.However, it is a great pity that the China stock market has never had a history of retail investors and institutions getting rich together. Don't deal with hot money and quantification! Foreign investment in A-shares has also become stale and has become fond of speculation. There are always too many routines to create A shares, which is too tiring to play, and the experience is really bad.

Yiming Food issued a suggestive announcement on the risk of stock trading. Since November 26, 2024, the company's stock has been trading daily for 11 consecutive times, with a cumulative turnover rate of 66.9%, which is a risk of a sharp decline in the short term. At the same time, several major shareholders reduced their holdings of shares not exceeding 1% of the total share capital. As of the close of December 10, 2024, the three partnership platforms reduced their holdings by 138,200 shares today.News:Wentai Technology: Shareholders plan to reduce their holdings by no more than 2%;

First, heavy! Shanghai merger and reorganization action plan announcedHaineng Industry: The controlling shareholder intends to reduce the company's shares by no more than 3%;Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.